When should low‑dose (81 mg) aspirin be discontinued in an elderly patient?

When to Discontinue Baby Aspirin in Elderly Patients

Low-dose aspirin (81 mg) should be discontinued in elderly patients (≥70 years) when used for primary prevention of cardiovascular disease, as the bleeding risk outweighs any potential benefit in this age group.

Primary Prevention Context

For patients ≥70 years without established cardiovascular disease, aspirin should not be routinely used and should be stopped if currently prescribed. 1

• The 2019 ACC/AHA guidelines explicitly state that low-dose aspirin (75-100 mg daily) should not be administered on a routine basis for primary prevention among adults >70 years of age (Class III: Harm recommendation, Level B-R evidence) 1
• This recommendation is based on increased bleeding risk that exceeds cardiovascular benefit in this age group 1
• The FDA label for aspirin warns that bleeding risk is higher in patients age 60 or older, particularly with stomach ulcers or bleeding problems 2

Bleeding Risk Considerations

• Aspirin increases major bleeding complications by a factor of 1.5 (median) across various procedures and clinical settings 3
• In elderly patients with atrial fibrillation, adding aspirin to anticoagulation increased major or clinically relevant non-major bleeding from 1.8% to 3.4% per year 4
• Recent evidence suggests long-term aspirin use may increase heart failure risk by 7% in individuals free of cardiovascular disease 5

Secondary Prevention Context (Established Cardiovascular Disease)

For elderly patients with documented atherosclerotic cardiovascular disease (prior MI, stroke, PCI, or CABG), aspirin should generally be continued indefinitely unless specific contraindications exist. 6, 7, 8

Post-PCI/Stent Management

The timing of aspirin discontinuation depends on the clinical scenario:

After PCI for stable ischemic heart disease (no recent ACS):

• Continue dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for at least 12 months 8
• After 12 months post-PCI, aspirin can be continued long-term as monotherapy 9

After PCI with concurrent atrial fibrillation requiring anticoagulation:

• Discontinue aspirin after 1-4 weeks while maintaining P2Y12 inhibitor plus oral anticoagulant 10
• For patients ≥65 years or CHADS₂ ≥1, the preferred regimen is aspirin 81 mg daily plus clopidogrel 75 mg daily plus reduced-intensity oral anticoagulant, with aspirin discontinued as early as the day following PCI 11
• Triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) is explicitly not recommended beyond the acute hospitalization period (Class III recommendation) 4

After CABG surgery:

• Continue aspirin (<100 mg daily) for 1 year post-CABG 9
• Stop aspirin 1 year post-CABG if patient requires oral anticoagulation for atrial fibrillation 9

Post-ACS Management

For elderly patients with recent acute coronary syndrome:

• Aspirin should be continued indefinitely (Class I recommendation) 6, 7, 8
• Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) should continue for up to 12 months 8
• The preferred maintenance dose is 81 mg daily, particularly when combined with ticagrelor 8

Medically Managed Stable Disease

For patients with peripheral artery disease or stable ischemic heart disease managed medically (no recent intervention):

• If oral anticoagulation is started for atrial fibrillation, aspirin can be stopped once the anticoagulant is initiated 9
• Antiplatelet therapy cannot replace oral anticoagulation for stroke prevention in atrial fibrillation 4

Special Scenario: New-Onset Atrial Fibrillation After MI

For elderly patients who develop atrial fibrillation within 12 months of acute MI:

• Stop aspirin immediately when starting apixaban 4
• Use apixaban plus clopidogrel (dual therapy) without aspirin as the optimal regimen (Class I, Level A recommendation) 4
• Continue this dual therapy for up to 12 months, then transition to apixaban monotherapy 4

Practical Deprescribing Approach

When discontinuing aspirin for primary prevention in elderly patients:

1. Identify eligible patients: Those ≥70 years on aspirin without documented ASCVD (no prior MI, stroke, PCI, CABG, or peripheral arterial disease) 1, 12

2. Patient communication: Pharmacist-led interventions achieve 60% deprescribing success rates with approximately 8 minutes of outreach time 12

3. Timing: Aspirin can be stopped immediately without tapering 12, 13

4. Follow-up: Studies show minimal increased risk of major adverse cardiovascular events after deprescribing in primary prevention patients, with potential reduction in gastrointestinal bleeding hospitalizations 14

Common Pitfalls to Avoid

• Do not continue aspirin in patients ≥70 years for primary prevention simply because they have been taking it for years 1
• Do not use prolonged triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) beyond 1-4 weeks in elderly patients with atrial fibrillation after PCI 10, 4
• Do not discontinue aspirin perioperatively in patients on secondary prevention without cardiology consultation, as cardiovascular events may occur 8.5 ± 3.6 days after discontinuation 3, 15
• Do not assume antiplatelet therapy can substitute for anticoagulation in atrial fibrillation; dual antiplatelet therapy is less effective than warfarin (5.6% vs 3.9% annual stroke rate, P=0.0003) 4